Radiance Biopharma has filed a notice of an exempt offering of securities to raise $30,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Radiance Biopharma is raising up to $30,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Brooks played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Radiance Biopharma
Radiance Biopharma, Inc. (Radiance) is a biotechnology company developing targeted cancer therapies using Antibody Drug Conjugates (ADCs). ADCs are designed to deliver greater efficacy and safety in treating cancer and other unmet clinical needs. Radiances Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer. RB-201 is a First-in-class fully human Bispecific ADC targeting both HER2 and TROP-2 conjugated with a protease-cleavable linker to monomethyl auristatin E payload. RB-203 is a based on a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells.
To learn more about Radiance Biopharma, visit http://radiancebio.com/
Contact:
Robert Brooks, Chief Executive Officer
617-621-7143
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.